Clevudine: a promising therapy for the treatment of chronic hepatitis B

[Guest guest]

Expert Opin Investig Drugs. 2008 Dec;17(12):1963-74.

Clevudine: a promising therapy for the treatment of chronic hepatitis B.

Asselah T, Lada O, Moucari R, Marcellin P.

Université Paris 7-Denis-Diderot, Hôpital Beaujon, Pôle des Maladies de

l'Appareil Digestif, Service d'Hépatologie, Centre de Recherche Biomédicale

Bichat Beaujon CRB3, INSERM U773. tarik.asselah@...

Chronic hepatitis B virus (HBV) infection, affecting approximately 350 million

people worldwide, is associated with significant morbidity and mortality. In the

past 10 years, hepatitis B therapy research has led to a multitude of available

antiviral therapies: IFN-alpha, pegylated IFN-alpha(2a), lamivudine, adefovir,

entecavir, telbivudine and tenofovir. To further improve reductions in viral

load and resistance profiles, development of new HBV therapeutic strategies has

been an important focus. One such therapy is clevudine, an analogue of the

beta-L configuration. Clevudine is already licensed in Korea for anti-HBV

therapy (Bukwang Pharmaceuticals, Seoul, Korea). Unique to clevudine is its

ability to maintain antiviral activity following discontinuation of therapy.

Typically, hepatitis B treatment requires continuous therapy to prevent

reactivation. Sustained response is uncommon except in hepatitis B antigen

(HBeAg)-positive patients who developed HBeAg seroconversion. This article

reviews chronic HBV and its therapy options. Specifically, it describes

clevudine's potent and sustained antiviral activity as observed in vitro and in

vivo.

PMID: 19012511 [PubMed - in process]

[Guest guest]

Expert Opin Investig Drugs. 2008 Dec;17(12):1963-74.

Clevudine: a promising therapy for the treatment of chronic hepatitis B.

Asselah T, Lada O, Moucari R, Marcellin P.

Université Paris 7-Denis-Diderot, Hôpital Beaujon, Pôle des Maladies de

l'Appareil Digestif, Service d'Hépatologie, Centre de Recherche Biomédicale

Bichat Beaujon CRB3, INSERM U773. tarik.asselah@...

Chronic hepatitis B virus (HBV) infection, affecting approximately 350 million

people worldwide, is associated with significant morbidity and mortality. In the

past 10 years, hepatitis B therapy research has led to a multitude of available

antiviral therapies: IFN-alpha, pegylated IFN-alpha(2a), lamivudine, adefovir,

entecavir, telbivudine and tenofovir. To further improve reductions in viral

load and resistance profiles, development of new HBV therapeutic strategies has

been an important focus. One such therapy is clevudine, an analogue of the

beta-L configuration. Clevudine is already licensed in Korea for anti-HBV

therapy (Bukwang Pharmaceuticals, Seoul, Korea). Unique to clevudine is its

ability to maintain antiviral activity following discontinuation of therapy.

Typically, hepatitis B treatment requires continuous therapy to prevent

reactivation. Sustained response is uncommon except in hepatitis B antigen

(HBeAg)-positive patients who developed HBeAg seroconversion. This article

reviews chronic HBV and its therapy options. Specifically, it describes

clevudine's potent and sustained antiviral activity as observed in vitro and in

vivo.

PMID: 19012511 [PubMed - in process]

[Guest guest]

Expert Opin Investig Drugs. 2008 Dec;17(12):1963-74.

Clevudine: a promising therapy for the treatment of chronic hepatitis B.

Asselah T, Lada O, Moucari R, Marcellin P.

Université Paris 7-Denis-Diderot, Hôpital Beaujon, Pôle des Maladies de

l'Appareil Digestif, Service d'Hépatologie, Centre de Recherche Biomédicale

Bichat Beaujon CRB3, INSERM U773. tarik.asselah@...

Chronic hepatitis B virus (HBV) infection, affecting approximately 350 million

people worldwide, is associated with significant morbidity and mortality. In the

past 10 years, hepatitis B therapy research has led to a multitude of available

antiviral therapies: IFN-alpha, pegylated IFN-alpha(2a), lamivudine, adefovir,

entecavir, telbivudine and tenofovir. To further improve reductions in viral

load and resistance profiles, development of new HBV therapeutic strategies has

been an important focus. One such therapy is clevudine, an analogue of the

beta-L configuration. Clevudine is already licensed in Korea for anti-HBV

therapy (Bukwang Pharmaceuticals, Seoul, Korea). Unique to clevudine is its

ability to maintain antiviral activity following discontinuation of therapy.

Typically, hepatitis B treatment requires continuous therapy to prevent

reactivation. Sustained response is uncommon except in hepatitis B antigen

(HBeAg)-positive patients who developed HBeAg seroconversion. This article

reviews chronic HBV and its therapy options. Specifically, it describes

clevudine's potent and sustained antiviral activity as observed in vitro and in

vivo.

PMID: 19012511 [PubMed - in process]

[Guest guest]

Expert Opin Investig Drugs. 2008 Dec;17(12):1963-74.

Clevudine: a promising therapy for the treatment of chronic hepatitis B.

Asselah T, Lada O, Moucari R, Marcellin P.

Université Paris 7-Denis-Diderot, Hôpital Beaujon, Pôle des Maladies de

l'Appareil Digestif, Service d'Hépatologie, Centre de Recherche Biomédicale

Bichat Beaujon CRB3, INSERM U773. tarik.asselah@...

Chronic hepatitis B virus (HBV) infection, affecting approximately 350 million

people worldwide, is associated with significant morbidity and mortality. In the

past 10 years, hepatitis B therapy research has led to a multitude of available

antiviral therapies: IFN-alpha, pegylated IFN-alpha(2a), lamivudine, adefovir,

entecavir, telbivudine and tenofovir. To further improve reductions in viral

load and resistance profiles, development of new HBV therapeutic strategies has

been an important focus. One such therapy is clevudine, an analogue of the

beta-L configuration. Clevudine is already licensed in Korea for anti-HBV

therapy (Bukwang Pharmaceuticals, Seoul, Korea). Unique to clevudine is its

ability to maintain antiviral activity following discontinuation of therapy.

Typically, hepatitis B treatment requires continuous therapy to prevent

reactivation. Sustained response is uncommon except in hepatitis B antigen

(HBeAg)-positive patients who developed HBeAg seroconversion. This article

reviews chronic HBV and its therapy options. Specifically, it describes

clevudine's potent and sustained antiviral activity as observed in vitro and in

vivo.

PMID: 19012511 [PubMed - in process]